# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Chardan Capital analyst Keay Nakae maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and maintains $33 price target.
Needham analyst Joseph Stringer reiterates Avidity Biosciences (NASDAQ:RNA) with a Buy and maintains $35 price target.
B of A Securities analyst Geoff Meacham initiates coverage on Avidity Biosciences (NASDAQ:RNA) with a Buy rating and announc...
Needham analyst Joseph Stringer reiterates Avidity Biosciences (NASDAQ:RNA) with a Buy and maintains $35 price target.
-3-ASR